MARKET

NBSE

NBSE

NeuBase Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.02
-0.15
-1.84%
Opening 13:33 08/13 EDT
OPEN
8.19
PREV CLOSE
8.17
HIGH
8.31
LOW
8.02
VOLUME
46.22K
TURNOVER
--
52 WEEK HIGH
11.78
52 WEEK LOW
4.150
MARKET CAP
185.42M
P/E (TTM)
-2.5130
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NBSE stock price target is 15.67 with a high estimate of 18.00 and a low estimate of 13.00.

EPS

NBSE News

More
NeuBase Therapeutics appoints industry veteran as COO
Seeking Alpha · 07/28 15:31
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 06/18 12:34
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16)
Benzinga · 06/16 12:15
RBC Capital Initiates Coverage On NeuBase Therapeutics with Outperform Rating, Announces Price Target of $16
RBC Capital analyst Brian Abrahams initiates coverage on NeuBase Therapeutics (NASDAQ:NBSE) with a Outperform rating and announces Price Target of $16.
Benzinga · 06/16 11:18
Is NeuBase Therapeutics, Inc. (NBSE) A Good Stock To Buy?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite inve
Insider Monkey · 06/10 20:20
Need To Know: NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Insiders Have Been Buying Shares
Simply Wall St. · 05/15 13:48
NeuBase Therapeutics EPS misses by $0.04
NeuBase Therapeutics (NASDAQ:NBSE): Q2 GAAP EPS of -$0.26 misses by $0.04. Cash and cash equivalents of ~$5.8M Press Release
seekingalpha · 05/15 01:26
Stocks That Hit 52-Week Highs On Monday
Monday's morning session saw 70 companies set new 52-week highs.
Benzinga · 05/11 14:29

Industry

Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
-1.21%

Hot Stocks

Symbol
Price
%Change

About NBSE

NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
More

Webull offers kinds of Neubase Therapeutics Inc stock information, including NASDAQ:NBSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBSE stock methods without spending real money on the virtual paper trading platform.